Immunosuppression on peripheral neuropathy: Rationale and reality

Current Opinion in Pharmacology

Volumn 2, Issue 3, 2002, Pages 291-295

  Sutton, Ian J ^a   Winer, John B ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; FLUDARABINE; GROWTH FACTOR; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; RITUXIMAB;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; MOTOR NEUROPATHY; PARAPROTEINEMIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0036605673     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00158-3     Document Type: Review

References (55)

1. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: Induction of experimental allergic neuritis (EAN) by PO protein-specific T cell lines
2. Synergy between antibody and P2-reactive T cells in experimental allergic neuritis
3. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
4. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les characteres clinique et graphique des reflexes tendinaux
5. Pathology of inflammatory demyelinating neuropathies
6. Campylobacter jejuni infection and Guillain-Barre syndrome
7. Antiganglioside antibodies in Guillain-Barre syndrome after a recent cytomegalovirus infection
8. Serum anti-GQ1b IgG antibody is associated with opthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: Clinical and immunohistochemical studies
9. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome
10. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure
11. Miller Fisher anti-GQ1b antibodies: Alpha-latrotoxin-like effects on motor end plates
12. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release
13. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value
14. Plasmapheresis and acute Guillain-Barre syndrome
15. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome
16. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy
17. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome
18. Combined therapy of intravenous immunoglobulin and methylprednisolone in patients with Guillain Barre Syndrome. The results of a multicentre double blind placebo controlled clinical trial
19. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome
20. Treatment of Guillain-Barre syndrome with anti-T cell monoclonal antibodies
21. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force
22. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
23. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study
24. Intravenous immunoglobulin (IVig) for chronic inflammatory demyelinating polyradiculoneuropathy: A cochrane systematic review
25. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
26. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study
27. PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy
28. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy
29. Natural history of 46 patients with multifocal motor neuropathy with conduction block
30. Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis-Summer syndrome
31. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates
32. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons
33. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study
34. Multifocal motor neuropathy: Diagnostic criteria that predict the response to immunoglobulin treatment
35. Multifocal motor neuropathy with conduction block: A study of 24 patients
36. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy
37. Deterioration of multifocal motor neuropathy after plasma exchange
38. Immunoadsorption in multifocal motor neuropathy
39. Multifocal motor neuropathy: Diagnosis and treatment
40. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
41. Chronic motor neuropathies: Response to interferon-beta1a after failure of conventional therapies
42. Treatment of multifocal motor neuropathy with interferon-beta1a
43. The monoclonal gammopathies (paraproteins)
44. Plasma cell dyscrasia and peripheral neuropathy: Identification of the myelin antigens that react with human paraproteins
45. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes
46. Neuropathy associated with 'benign' anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases
47. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies
48. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study
49. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies
50. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy
51. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undertermined significance
52. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine
53. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with rituxan
54. Monoclonal proteins in neuropathy
55. Prevalence of monoclonal protein in peripheral neuropathy